GLYC GlycoMimetics Inc.

4.56
-0.13  -3%
Previous Close 4.69
Open 4.71
Price To Book 1.18
Market Cap 197,721,367
Shares 43,359,949
Volume 120,613
Short Ratio
Av. Daily Volume 267,423
Stock charts supplied by TradingView

NewsSee all news

  1. GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China

    GlycoMimetics to receive an upfront cash payment with eligibility to receive development, regulatory, and sales-based milestones, and tiered royalties Apollomics

  2. GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019

    GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Piper Jaffrey 31st Annual Healthcare Conference in New York, New York, which takes place

  3. GlycoMimetics to Present at Two Upcoming Investor Conferences

    GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that company executives will provide a corporate update at two upcoming investor relations conferences in November. Details are as follows: STIFEL HEALTHCARE

  4. GlycoMimetics Reports Third Quarter 2019 Financial Results and Recent Operational Developments

    Advanced its Phase 3 program for uproleselan in acute myeloid leukemia (AML) through both Company-sponsored and NCI-sponsored clinical trials Announced abstracts accepted for presentation in December at the Annual

  5. GlycoMimetics to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at 61st ASH Meeting

    Latest analysis of clinical data on novel therapeutic candidate will be shared, showing that uproleselan can augment deep clinical responses and prolong overall survival in high risk patients with acute myeloid

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data due 2021.
Uproleselan (GMI-1271)
Acute myeloid leukemia (AML) newly diagnosed and refractory - cancer
Phase 3 data failed to meet endpoints - August 2, 2019.
GMI-1070 (rivipansel)
Vaso-occlusive crisis of sickle cell disease
Phase 1 ongoing.
GMI-1271
Multiple myeloma
Proof of concept trial to be initiated 2H 2019.
GMI-1359
Hormone receptor positive metastatic breast cancer
Phase 3 commencement of enrolment announced April 23, 2019.
Uproleselan (GMI-1271) - NCI
Acute myeloid leukemia (AML)

Latest News

  1. GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China

    GlycoMimetics to receive an upfront cash payment with eligibility to receive development, regulatory, and sales-based milestones, and tiered royalties Apollomics

  2. GlycoMimetics to Present at the Piper Jaffrey 31st Annual Healthcare Conference 2019

    GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the Piper Jaffrey 31st Annual Healthcare Conference in New York, New York, which takes place

  3. GlycoMimetics to Present at Two Upcoming Investor Conferences

    GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that company executives will provide a corporate update at two upcoming investor relations conferences in November. Details are as follows: STIFEL HEALTHCARE

  4. GlycoMimetics Reports Third Quarter 2019 Financial Results and Recent Operational Developments

    Advanced its Phase 3 program for uproleselan in acute myeloid leukemia (AML) through both Company-sponsored and NCI-sponsored clinical trials Announced abstracts accepted for presentation in December at the Annual

  5. GlycoMimetics to Present Further Analysis of Data From Phase 1/2 AML Trial of Uproleselan at 61st ASH Meeting

    Latest analysis of clinical data on novel therapeutic candidate will be shared, showing that uproleselan can augment deep clinical responses and prolong overall survival in high risk patients with acute myeloid

  6. GlycoMimetics to Report Third Quarter 2019 Financial Results on November 7, 2019

    GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that it will host a conference call and webcast to report its third-quarter 2019 financial results on Thursday, November 7, 2019, at 8:30 a.m. ET. The dial-in number

  7. GlycoMimetics to Present at Two Upcoming Investor Conferences

    GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that Chief Executive Officer Rachel King will provide a corporate update at two upcoming investor relations conferences in New York, NY in September. Details are as